TQB-3525 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TQB-3525’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TQB-3525 overview

TQB-3525 is under development for the treatment of metastatic advanced endometrial cancer, cervical cancer, ovarian cancer, relapsed and refractory mantle cell lymphoma, relapsed and refractory diffuse large B-cell lymphoma, non-small cell lung cancer, advanced solid tumors, relapsed/refractory peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), marginal zone b-lymphoma, relapsed, refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed and refractory follicular lymphoma. It acts by targeting isoforms of phosphoinositide 3-kinase (PI3K alpha/delta).

The drug candidate is formulated as tablet administered through oral route.

It was also under development for the treatment of human epidermal growth factor receptor 2 negative breast cancer and relapsed and refractory mantle cell lymphoma.

Chia Tai Tianqing Pharmaceutical Group overview

Chia Tai Tianqing Pharmaceutical Group (CTTQ) subsidiary of Sino Biopharmaceutical Ltd, is a pharmaceutical company that offers integrated R&D, manufacturing, marketing, sales and distribution services. The company manufacture prescription medicines in various core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes. CTTQ produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, and liver disease. The company operates through its technology and research and development centers in Jiangsu. Its APIs and FDFs are sold to all major continents including Americas, Europe, Asia, and Africa. CTTQ is headquartered in Lianyungang, Nanjing, China.

For a complete picture of TQB-3525’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.